JP2008539169A5 - - Google Patents

Download PDF

Info

Publication number
JP2008539169A5
JP2008539169A5 JP2008507834A JP2008507834A JP2008539169A5 JP 2008539169 A5 JP2008539169 A5 JP 2008539169A5 JP 2008507834 A JP2008507834 A JP 2008507834A JP 2008507834 A JP2008507834 A JP 2008507834A JP 2008539169 A5 JP2008539169 A5 JP 2008539169A5
Authority
JP
Japan
Prior art keywords
treatment
immunostimulant
medicament
disease
prevention
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2008507834A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008539169A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2006/014720 external-priority patent/WO2006113792A2/en
Publication of JP2008539169A publication Critical patent/JP2008539169A/ja
Publication of JP2008539169A5 publication Critical patent/JP2008539169A5/ja
Pending legal-status Critical Current

Links

JP2008507834A 2005-04-19 2006-04-19 疾患における免疫学的介入のための一価および多価合成多糖類抗原 Pending JP2008539169A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67280705P 2005-04-19 2005-04-19
PCT/US2006/014720 WO2006113792A2 (en) 2005-04-19 2006-04-19 Monovalent and polyvalent synthetic polysaccharide antigens for immunological intervention in disease

Publications (2)

Publication Number Publication Date
JP2008539169A JP2008539169A (ja) 2008-11-13
JP2008539169A5 true JP2008539169A5 (https=) 2009-06-04

Family

ID=37115904

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2008507834A Pending JP2008539169A (ja) 2005-04-19 2006-04-19 疾患における免疫学的介入のための一価および多価合成多糖類抗原

Country Status (8)

Country Link
US (1) US20090214598A1 (https=)
EP (2) EP2407178A2 (https=)
JP (1) JP2008539169A (https=)
KR (1) KR20070122563A (https=)
CN (1) CN101448517A (https=)
AU (1) AU2006236294A1 (https=)
CA (1) CA2605321A1 (https=)
WO (1) WO2006113792A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7850949B2 (en) 2006-09-29 2010-12-14 Michigan Technological University Purification of synthetic oligomers
US9138470B2 (en) * 2007-11-02 2015-09-22 The Johns Hopkins University Multi-component L2 vaccine for prevention of human papilloma virus infection
WO2010003178A1 (en) * 2008-07-07 2010-01-14 The University Of Melbourne A synthetic vaccine component
WO2012047639A2 (en) 2010-09-27 2012-04-12 Michigan Technological University Purification of synthetic oligonucleotides
BR112017021970A2 (pt) * 2015-04-17 2018-07-10 Symic Ip Llc bioconjugados e usos dos mesmos
SG11201911430PA (en) 2017-07-04 2020-01-30 Curevac Ag Novel nucleic acid molecules
AU2018298224B2 (en) * 2017-07-07 2024-08-15 Symic Ip, Llc Synthetic bioconjugates
WO2020060491A1 (en) * 2018-09-19 2020-03-26 Nanyang Technological University Biohybrid peptidoglycan oligomers
WO2025088088A1 (en) 2023-10-27 2025-05-01 CureVac SE Rna composition for improving cell therapy

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
SU727647A1 (ru) 1977-11-02 1980-04-15 Институт биоорганической химии им.М.М.Шемякина Гликопептиды,обладающие противоопухолевой активностью и способ их получени
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US6024964A (en) 1985-06-24 2000-02-15 Hoechst Aktiengesellschaft Membrane anchor/active compound conjugate, its preparation and its uses
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5864008A (en) 1988-03-25 1999-01-26 James; Stephen Peptides derived from foot-and-mouth disease virus, pharmaceutical compositions, and methods for using the peptides
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
US6423315B1 (en) 1993-03-03 2002-07-23 The University Of Tennessee Research Corp. Synthetic peptide for treatment of autoimmune arthritis
AUPM885194A0 (en) 1994-10-14 1994-11-10 Council Of The Queensland Institute Of Medical Research, The Synthetic peptides and vaccines comprising same
EP1172376A1 (en) 1994-11-18 2002-01-16 Neurocrine Biosciences, Inc. Peptide analogues at position 91 of human myelin basic protein for treatment of multiple sclerosis
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
WO1997005889A1 (en) * 1995-08-03 1997-02-20 Slesarev Vladimir I Non-specific vaccination by d-amino-acid containing compounds
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
IL120503A0 (en) 1997-03-20 1997-07-13 Hadasit Med Res Service Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
US6107021A (en) 1998-06-20 2000-08-22 United Biomedical, Inc. Synthetic peptide vaccines for foot-and-mouth disease
JP4699612B2 (ja) 1999-02-05 2011-06-15 ザ ユニバーシティ オブ メルボーン Ｔヘルパー細胞エピトープ
FR2797202B1 (fr) 1999-08-02 2001-10-26 Genomic Equipement pour l'extraction automatique d'acides nucleiques
WO2003014957A1 (en) 2001-08-03 2003-02-20 Porto Ranelli, S.A. Identification of users on a network
US20030033351A1 (en) 2001-08-10 2003-02-13 Aleta Ricciardi Group proxy and method for grouping services in a distributed computing application
WO2003015815A1 (en) * 2001-08-21 2003-02-27 The Brigham And Women's Hospital, Inc. Improved conjugate vaccines
AU2003209623A1 (en) 2002-02-19 2003-09-09 Yeda Research And Development Co. Ltd. Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation
CN1200590C (zh) 2002-03-01 2005-05-04 华为技术有限公司 一种实现gsm与cdma网络信令互通的方法
AU2003217685A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Immunomodulatory polymeric antigens for treating inflammatory pathogies
AU2003250586B2 (en) 2002-08-12 2010-09-23 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes
BR0313101A (pt) 2002-08-12 2005-06-28 Queensland Inst Med Res Novos lipopeptìdeos imunogênicos que compreendem epitopos de linfócitos t-helper e linfócitos t citotóxicos (ctl), e métodos para sua produção e uso
US7420037B2 (en) 2003-02-13 2008-09-02 Antigenics Inc. Heat shock protein-based vaccines and immunotherapies
EP1617804A4 (en) 2003-04-11 2007-07-25 Antigenics Inc IMPROVED VACCINE BASED ON HEAT SHOCK PROTEINS AND IMMUNOTHERAPIES
CN100554279C (zh) * 2003-09-17 2009-10-28 伊莱利利公司 用于疾病免疫干预的合成多糖抗原

Similar Documents

Publication Publication Date Title
JP2011006431A5 (https=)
HRP20150770T1 (hr) Terapijska kombinacija koja sadrži dolutegravir, abakavir i lamivudin
JP2007527914A5 (https=)
JP2012255026A5 (https=)
ME02558B (me) Inhibitori replikacije virusa gripa
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
WO2011157741A3 (en) Human antibody drug conjugates against tissue factor
JP2015057451A5 (https=)
EA200901423A1 (ru) Бензимидазолы и содержащие их фармацевтические композиции
JP2020097577A5 (https=)
EA201071204A1 (ru) Применение дронедарона для приготовления лекарственного средства для применения в предотвращении госпитализации в кардиологическое отделение или смертности
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2014503593A5 (https=)
JP2016510326A5 (https=)
ATE505203T1 (de) Pharmazeutische kombination aus aliskiren und valsartan
JP2009537554A5 (https=)
NO20082047L (no) Sakte frigivende sammensetning, fremgangsmate for fremstilling derav og anvendelse av samme
HRP20171742T4 (hr) 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom
JP2008539169A5 (https=)
JP2007238598A5 (https=)
JP2010500284A5 (https=)
MY139086A (en) Use of debranched starch in extrusion-spheronization pharmaceutical pellets
JP2013523758A5 (https=)
JP2014148552A5 (https=)
CL2013003176A1 (es) Formulacion farmaceutica oral de liberacion sostenida que comprende dos tabletas que contienen 1000 mg de paracetamol, el cual esta presente en una capa de liberacion sostenida y otra de liberacion inmediata, en una proporcion de paracetamol por capa de 80-90 %: 10-20 %, donde la dosis unitaria comprende 2000 mg de paracetamol.